TF and prostate cancer: In addition, the total of 17,435 TADs were detected from the Hi-C data for prostate cancer, including 304 TADs enriched with disease-associated SNPs; 291 of these SNP-rich TADs contain enhancers (7940 in total) and 241 contain TF binding sites (686 in total).